Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Payables (2020 - 2025)

Historic Payables for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $8.9 million.

  • Evoke Pharma's Payables rose 2404.13% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 2404.13%. This contributed to the annual value of $7.3 million for FY2024, which is 937.77% up from last year.
  • Per Evoke Pharma's latest filing, its Payables stood at $8.9 million for Q3 2025, which was up 2404.13% from $8.6 million recorded in Q2 2025.
  • Evoke Pharma's Payables' 5-year high stood at $8.9 million during Q3 2025, with a 5-year trough of $519001.0 in Q2 2021.
  • Its 5-year average for Payables is $4.3 million, with a median of $6.4 million in 2023.
  • As far as peak fluctuations go, Evoke Pharma's Payables tumbled by 3137.19% in 2021, and later soared by 67810.27% in 2023.
  • Quarter analysis of 5 years shows Evoke Pharma's Payables stood at $874028.0 in 2021, then grew by 6.9% to $934312.0 in 2022, then surged by 618.37% to $6.7 million in 2023, then grew by 9.38% to $7.3 million in 2024, then increased by 21.46% to $8.9 million in 2025.
  • Its Payables was $8.9 million in Q3 2025, compared to $8.6 million in Q2 2025 and $7.8 million in Q1 2025.